Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
tivozanib fibroblast growth factor receptor 1 small molecule NA drugbank Renal Cell Carcinoma[MeSHID:D002292]
Disease Progression[MeSHID:D018450]
Disease[MeSHID:D004194]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
tivozanib vascular endothelial growth factor receptor 1 small molecule Successful target TTD , drugbank , DGIDB Renal Cell Carcinoma[MeSHID:D002292]
Disease Progression[MeSHID:D018450]
Disease[MeSHID:D004194]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.87 approved,investigational inhibitor
tivozanib receptor-type tyrosine-protein kinase flt3 small molecule NA drugbank Renal Cell Carcinoma[MeSHID:D002292]
Disease Progression[MeSHID:D018450]
Disease[MeSHID:D004194]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
tivozanib vascular endothelial growth factor receptor 3 small molecule Successful target TTD , drugbank , DGIDB Renal Cell Carcinoma[MeSHID:D002292]
Disease Progression[MeSHID:D018450]
Disease[MeSHID:D004194]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.85 approved,investigational inhibitor
tivozanib vascular endothelial growth factor receptor 2 small molecule Successful target TTD , drugbank , DGIDB Renal Cell Carcinoma[MeSHID:D002292]
Disease Progression[MeSHID:D018450]
Disease[MeSHID:D004194]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 0.54 approved,investigational inhibitor
tivozanib mast/stem cell growth factor receptor kit small molecule NA drugbank Renal Cell Carcinoma[MeSHID:D002292]
Disease Progression[MeSHID:D018450]
Disease[MeSHID:D004194]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
tivozanib hepatocyte growth factor receptor small molecule NA drugbank Renal Cell Carcinoma[MeSHID:D002292]
Disease Progression[MeSHID:D018450]
Disease[MeSHID:D004194]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
tivozanib platelet-derived growth factor receptor alpha small molecule NA drugbank Renal Cell Carcinoma[MeSHID:D002292]
Disease Progression[MeSHID:D018450]
Disease[MeSHID:D004194]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
tivozanib platelet-derived growth factor receptor beta small molecule NA drugbank Renal Cell Carcinoma[MeSHID:D002292]
Disease Progression[MeSHID:D018450]
Disease[MeSHID:D004194]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational inhibitor
tivozanib protein-tyrosine kinase 6 small molecule NA drugbank Renal Cell Carcinoma[MeSHID:D002292]
Disease Progression[MeSHID:D018450]
Disease[MeSHID:D004194]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational unknown
tivozanib angiopoietin-1 receptor small molecule NA drugbank Renal Cell Carcinoma[MeSHID:D002292]
Disease Progression[MeSHID:D018450]
Disease[MeSHID:D004194]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 NA approved,investigational unknown
click here to return to the previous page